ƒ( t, l, c ) The Use of Botox Injection in the Treatment of the Neurogenic Bladder Bladder ( Sphincter ) Dysfunction Dr C K Chan 95%
|
|
- June Thompson
- 5 years ago
- Views:
Transcription
1 The Use of Botox Injection in the Treatment of the Neurogenic Bladder Dr C K Chan Division of Urology Department of Surgery Prince of Wales Hospital EAU guidelines 2003 / 2006 Neurologic disease Dementia ( % ) Parkinson s disease ( 38 70% ) Stroke ( 20 50% ) Cerebral tumour ( 24 % ) Cerebral palsy ( 36% ) Shy-Drager syndrome ( 100% ) Multiple sclerosis ( 50 90% ) Traumatic injury ( majority ) Haematoma syringomyelia Compression (e.g. tumour, Cervical spondylosis) ( 28 87% ) Disc prolapse ( 6 18% ) ( 28 87% ) Myelitis Spina bifida ( % ) Sacral agenesis Cauda equina disease Pelvic disease Pelvic surgery ( 10 60% ) Childbirth injury Diabetes mellitus ( 35 50%, type 2 : 87% ) Alcohol Abuse ( 5 60% ) B.C. Balkan War ( ) 95% Mortality of spinal cord injury due to renal problems in the past 90 years ( Donnelly J et al 1972; Borges PM et al 1982) World War I ( ) 80% World War II ( ) 40% Foley, June 1935.one having a dislocation in a vertebra of his neck, while he is unconscious of his two legs and two arms and his urine dribbles. An ailment not to be treated. Korean War ( ) 25% Vietnam War ( ) 5-10% Life expectancy for persons who survive the 1 st year post spinal cord injury ( years) ( National spinal cord injury database USA) 1995 Bladder ( Sphincter ) Dysfunction Age at injury NO spinal Functional at any level l Paraplegia Tetraplegia ( C 5-8 ) Tetraplegia ( C 1-4 ) Ventilator Dependent cord at any level injury ƒ( t, l, c ) t = time from diease / injury, l = level of disease / injury, c = completeness of disease / injury 1
2 Neurologic disease Dementia Parkinson s disease Stroke Cerebral tumour Cerebral palsy Shy-Drager syndrome ( Multiple System Atrophy ) Bladder dysfunction Inappropriate toilet behaviour Detrusor hyper-reflexia + co-ordinated external urethral sphincter and bladder neck activity Incontinence Multiple sclerosis Hyper-reflexic with UNcoordinated Traumatic injury external urethral sphincter and Compression Uncoordinated bladder neck (e.g. tumour, ( Autonomic dys-reflexia if lesion Cervical spondylosis) above T6 ) Myelitis Sensory impairment Spina bifida Incontinence / incomplete bladder emptying Level of Spinal Cord Dysfunction in Relation to Vesico-Urethral Dsfnction Dysfunction Sacral agenesis Cauda equina disease Pelvic disease Childbirth injury Diabetes mellitus Areflexic / underactive bladder with denervated / underactive sphincter BUT coordinated bladder neck Sensory impairment Incontinence / incomplete bladder emptying Spinal Cord Injury Incidence of spine injury by highest level ( Northwestern University Acute Spine Injury Centre ) Meyer 1994 Complete tetraplegia 25% Incomplete tetraplegia 25% Complete paraplegia 25% Incomplete paraplegia 25% Urinary problem in spinal cord dysfunction Urodynamic findings by level(s) of spinal cord injury. Spinal level No. of pts D H + DESD + D H + DESD - D A Normal cervical N=104 55% 30% 15% 0% Blavivas 1996 N=114 Weld % 42% 0% 0% Thoracic N=87 Blavivas % 10% 0% 0% Lumbar sacral mixed N=54 Weld % 50% 0% 0% N=61 Blavivas % 30% 40% 0% N=28 Weld % 32% 21% 4% N=32 Blavivas % 12% 64% 12% N=14 Weld % 14% 86% 0% N=33 Weld % 33% 27% 3% DH= detrusor hyper-reflexia ; DESD=detrusor external sphincter dys-synergia DA=detrusor areflexia Normal Voiding Detrusor external sphincter dys-synergia Level of lesion Initial Management of Neuropathic Bladder Peripheral n lesion Pelvic operation Lumbar disc prolapse Suprasacral infrapontine Lesion Trauma / multiple sclerosis Suprapontine Lesion Parkinson s disease CVA Clinical Assessment General Assessment Voiding diary / questionnaire ; QoL ; Physical Examiation Urinalysis / urine culture -> treat UTI if present Urinary tract imaging, renal function PVR by u/s Presumed diagnosis Treatment Sphincter deficiency Poor voiding Intermittent catheterization Neurogenic detrusor overactivity Cooperative pt Mobile pt Behavioural Modification Anti-muscarinics Uncooperative pt Immobile pt External appliance Indwelling catheter SP catheter Specialized Management 2
3 Level of lesion Clinical Assessment Diagnosis Treatment Specialized Management of Neuropathic Bladder Peripheral n lesion Pelvic operation Lumbar disc prolapse Urodynamics ( VCMG / EMG ) Urinary tract imaging Sphincter deficiency Timed voiding Ext. appliance Bulking agents AUS Sling Poor voiding IC Alpha blocker Intravesical electrostimulation SDAF : sacral deafferenation SARS : sacral anterior root stimulation IC : intermittent catheterization DESD : detrusor external sphincter dys-synergia Suprasacral infrapontine Lesion Trauma / multiple sclerosis Neurogenic detrusor overactivity No DESD DESD + Triggered voiding Anti-muscarinics IC Neurostimulation Anti-muscarinics IC SDAF + IC SDAF + SARS Sphincterotomy Bladder Augmentation + IC Urinary diversion Suprapontine Lesion Parkinson s disease CVA Suprapontine NDO Behavioural Modification Anti-muscarinics Neurostimulation Bladder augmentation Ext appliances IC Anti-muscarincs Adverse Effects of Oral Anti-muscarinics dry mouth, tachycardia, blurred vision, gastrointestinal effects (narrow angled ) glaucoma + CNS effect e.g. poor concentration, confusion The most common adverse effect is dry mouth But blurred vision and CNS effects will render patients to discontinue medication Intravesical Oxybutynin Intravesical Therapies for Neuropathic Bladder Apart From Oral Pharmacotherapay Buyse et al 1985 Brendler et al 1989 Greenfield et al 1991 Madersbacher et al 1995 Haferkamp et al mg / kg per day 5 mg oxybutynin / 15 ml Normal Saline Keep in bladder till next catheterization 61-87% continence rate Buyse et al Eur J Ped Surg 1985 ; 5 ( Suppl. 1 ) Brendler et al J Urol; 141: Greenfield et al J Urol 1991 ; 146 : Madersbacher et al Eur Urol 1995 ; 28 : Kaplinsky et al J Urol 1996 ; 156 : Haferkamp et al Spinal Cord ( 2000 ) 38, Intravesical Oxybutynin Intravesical Oxybutynin Haferkamp et al Spinal Cord ( 2000 ) 38, Guerra: J. urol., Volume 180(3).September
4 Capsaicin ( 1989 ) / 16 x 10 6 Units Scoville Heat Scale U Capsaicin 1mM; 100ml ; 30min; LA / GA ( ICS committee 2002 ) Pretreatment Post-treatment capacity capacity 144ml 267ml (72-195) ( ) Subjective clinical improvement 72% ( %) Vanilloid receptor 1 Non-selective ion channel Intravesical instillation Initial stimulation-> pain +++ then desensitizes C-fibre Long-lasting suppression Micturition reflex in neurologic disease: Predominant afferent input from bladder is through C-fibre Capsaicin Petersen et al : NO benefit Petersen et al Scand J Urol Nephrol. 1999; 33: Lazzeri M et al Spinal Cord 1999; 37 : Lazzeri M et al Urol Int 2004; 72: de Seze et al J Urol 2004 ; 171 : Lazzeri et al: NO benefit Autonomic dys-reflexia 12.96% Urgency incontinence 35.18% Pain 96% de Seze et al: When diluted in glucidic acid, few adverse events Capsaicin / Resiniferatoxin 1mM; 100ml ; 30min; LA / GA 1000x more potent sensory antagonist VR-1 NO prior excitatory effect-> NO PAIN Direct desensitization 100ml nM in 10% alcohol solution Instillation for 30 min Pretreatment post-treatment capacity capacity 175(±36) ml 281(±93) ml (Lazzeri et al 1998) Incontinence decreased by 1 2 episodes (Rivas et al 1999) Capsaicin / Resiniferatoxin -Reduction of nerve density of suburothelial innervations -Reduction in the expression of TRPV1 and P2X receptors Brady C.M. et al Eur Urol 2004 ; 46 : Brady C.M. et al BJU Int 2004; 93 : efficacy of improvement 92% Silva et al 2000 Eur Urol 38: Degree of neurological deficit 4
5 Time line of the discovery of Clostridium Botulinum toxin and its medicinal use 1817: German physician and poet Justinus Kerner described botulinium toxin, using the terms "sausage poison" and "fatty poison", as this bacterium often causes poisoning by growing in badly handled or prepared meat products. 1870: Müller (another German physician) coined the name botulism from Latin botulus = "sausage". 1895: Prof. Pierre Emile van Ermengem of Ellezelles first isolated the bacterium Clostridium botulinum. ( Gram +ve, rod-shaped anaerobic Clostridium botulinum ) 1923 Dickson et al ; Effect of botulinum toxin upon the autonomic nervous system 1944: cultured Clostridium botulinum and isolated the toxin 1949: Burgen's group discovered that botulinum toxin blocks neuromuscular transmission 1973: Alan B Scott used botulinium toxin type A (BTX-A) in monkey experiment 1980: Alan B Scott used BTX-A for the first time in humans to treat strabismus Time line of the discovery of Clostridium Botulinum toxin and its medicinal use in Urology 1967 Carpenter ; motor responses of bladder following botulinum toxin intoxication in cats 1999: Stohrer et al ; detrusor hyper-reflexia 2000: Schurch et al ; detrusor hyper-reflexia in spinal cord injured patients 2002: Reitz et al ; 184 patients with detrusor hyper-reflexia treated with botulinum toxin injection 1989: BTX-A (BOTOX) was approved by the US FDA for the treatment of strabismus, blepharospasm, and hemifacial spasm in patients over 12 years old 2002: FDA announced the approval of botulinum toxin type A (BOTOX Cosmetic) to temporarily improve the appearance of moderate-to-severe frown lines between the eyebrows (glabellar lines). Immunological subtypes of Botulinum Toxin International Standards for Clostridium botulinum Antitoxin A B Clostridium botulinum Clostridium botulinum C1 Clostridium botulinum D Clostridium botulinum E Clostridium butyricum F Clostridium baratii G Clostridium argentinense Immunological subtypes of Botulinum Toxin A, B, C1, D, E, F, and G Botulinum type A toxin ( BTX-A): Botox USA Dysport United Kingdom Botulinum type B toxin ( BTX-B): Myobloc USA NeuroBloc Europe 1 gm aerosolized botulinum toxin can kill 1.5 million population 1 ng = 20 units 1 unit = 0.05 ng Lethal dose for 70 kg human : ug ( IV / IM ) ug ( inhalation ) 70 ug ( po ) 5
6 Botulinum Toxin ( Botox ; Dysport; Myobloc ) BTX Protein Commercial Molecular Preparation Formulation Subtypes Target preparation Weight Units (kda) BTX-A SNAP-25 BOTOX Vacuum dried Dysport Lyophilized BTX-B VAMP/ Myobloc Solution Synaptobrevin Blockade of the motor and autonomic cholinergic junctions BTX-C Syntaxin N.A. BTX-D VAMP/ N.A. Synaptobrevin Cellubrevin BTX-E SNAP-25 N.A. BTX-F VAMP/ N.A. Synaptobrevin Cellubrevin BTX-G VAMP N.A. Illustration depicting nerve pathways targeted by botulinum toxin to treat lower urinary tract dysfunction Inhibition of acetylcholine exocytosis by BTX-A Smith CP and Chancellor MB (2004) J Urol 171: The circle with shading represents the prostate gland and the rectangle with shading represents the external urethral sphincter. Positive (+) signs represent sites of nerve activity and the negative (-) sign with associated arrows depicts locations where botulinum toxin may have inhibitory effects. Botulinum toxin in urology: evaluation using an evidence-based medicine approach Christopher P Smith, George T Somogyi and Timothy B Boone Nature Clinical Practice Urology (2004) 1, Afferent Denervation Afferent Denervation A schematic diagram of ultrastructural components of the human bladder wall Apostolidis A et al Eur Urol 2006 ; 49: BTX-A may inhibit neurotransmitter release and reduce sensory nerve excitability decrease urgency, frequency and pain 6
7 Botulinum Toxin Detrusor Injection for Detrusor Hyperreflexia Botulinum toxin ( Botox ; Dysport ) flexible cystoscope superfine 27-gauge disposable needle BOTOX (Allergan, Irvine, CA) Bladder wall, avoiding the trigone. 30 different injections, Each containing 10 units of BOTOX (1 ml), equally spaced points 200 units vs 300 units Botulinum toxin ( Botox ; Dysport ) Botulinum toxin ( Botox ; Dysport ) ml per injection Larger dilution volume -> greater suburothelial diffusion-> BTX act on larger surface of detrusor?? Extravasation?? Avoid Trigone? Avoid Dome ( intraperitoneal puncture -> bowel injury) Outpatient vs Inpatient LA vs Anaesthesia Cleveland Clinic Protocol ( Rackley et al 2005 ) Antibiotics 100 ml 2% lignocaine -> bladder x min 10 units in 1 ml saline Avoid shaking ( to minimize disulphide bond disruption) Priming of needle sheath ( ~ 0.5 ml ) Injection in even distribution Submucosal injection vs direct detrusor injection Continence rate according to the diluent volume Botulinum toxin ( Botox ; Dysport ) Botulinum toxin ( Botox ; Dysport ) Schulte-Baukloh et al BJU Int 2005; 454 Flexible injection needle ( 27G ) in use for giving intradetrusor botulinum toxin 10 units / ml / site x sites sparing trigone Schurch et al 2001 Max. bladder capacity 296 -> 480 ml (p p<0.016) Max. detrusor voiding pressure 65 -> 35 cmh2o ( p<0.016) At 6 wks: 89.5% continent At 36wks: 64.7% continent? effect 7
8 Botulinum toxin ( Botox ; Dysport ) Botulinum toxin ( Botox ; Dysport ) flexible cystoscope superfine 27-gauge disposable needle BOTOX (Allergan, Irvine, CA) Bladder wall, avoiding the trigone. 30 different injections, Each containing 10 units of BOTOX (1 ml), equally spaced points Bagi et al 2004 Before BTX-A Injection After BTX-A Injection Incontinence ( n ) 15 ( 100% ) 2 ( 13% )** Leaked volume ( ml/d ) 700 ( ) 0 ( )*** PdetMax ( cmh2o ) 86 ( ) 35 ( 5 73 )*** Volume-Pdet < 40cmH2O ( ml ) Max bladder capacity ( ml ) 185 ( ) 434 ( ) 350 ( ) 457 ( )** ** p< 0.01, McNemar ; *** p< 0.005, Wilcoxon Optimal dose? Best method of injection? Suburethral / intramural injection? Durability? Outcome measure? Cost Benefit? Suburothelial injection 100U 150U 200U Difficult voiding % 70% AROU % 20% Kuo et al AUA 2006 May Abstract 347 ; Urology 2005 ; 66: 94-8 effect? 3 months Post injection of Dysport to Detrusor # T11; NDO ; incontinence # T11 The Urodynamic Parameters at Baseline and after Botulinum Toxin Injection Baseline Post-Botox Statistics * Capacity (n=5) 331.4± ± Qmax (n=5) 6.7± ± Voiding pressure (n=5) 62.0± ± MUCP (n=5) 97.1± ± PVR (n=5) 225.4± ± MUCP=maximal urethral closure pressure, FPL=functional profile length, PVR= postvoid residual volume *Comparison between baseline and 4 weeks after treatment Schurch et al J Urol 2000; 164 ( 3Pt 1 ) :
9 % patients who are completely continent following injection of BTX to bladder Urodynamic changes following injection of BTX to bladder %complete conti nence volume in cc mean reflex vol. mean cystometric capacity 0 pre-injection 6wk postbtx 26wk postbtx 39wk postbtx 0 pre-injection 6wk postbtx 26wk postbtx Tow et al Ann Acad Med Singapore 2007 ; 36; 11-7 Tow et al Ann Acad Med Singapore 2007 ; 36; 11-7 Urodynamic changes following injection of BTX to bladder maximal detrusor pre essure cmh2o max pdet cmh2o pre-injection 6wk postbtx 26wk postbtx Authors No. pts Dose ( U ) Outcome Duration ( months ) Bagi et al trigone sparing 87% dry; 13% minor 7 ( 4 12 ) leak; pdetmax; cystometric capacity Schurch et al trigone sparing 89% dry at 6 wk; 9 cystometric capacity; mean reflex vol; pdetqmax Schurch et al trigone sparing Improved continence; 6 cystometric capacity; mean reflex vol; pdetmax Reitz et al trigone sparing Improved continence; 9 cystometric capacity; mean reflex vol. ; pdetqmax Schulte-Baukloh et al trigone sparing Improved continence; cystometric capacity; mean reflex volume; pdetmax Hajebrahimi et al trigone sparing Improved continence; 3+ mean reflex volume; cystometric capacity; pdetmax Tow et al Ann Acad Med Singapore 2007 ; 36; 11-7 Detrusor External Sphincter Dys-synergia 9
10 Botox Detrusor External Sphincter Dys-synergia Botulinum toxin ( Botox ; Dysport ) Detrusor External Sphincter Dys-synergia First Report : Dysktra et al J Urol 1988 ; 139 : Antibiotics 10 units in 1 ml saline Avoid shaking ( to minimize disulphide bond disruption) Standard cystoscope Collagen injection needle Priming of needle sheath ( ~ 0.5 ml ) Localization of external urethral sphincter : contraction of sphincter by patient / Valsalva manoeuvre 3, 6, 9, 12 o clock vs 2, 10 o clock Injection of 3,6, 9, and 12 o clock Position of Urethral Sphincter NDO + DESD NDO + DESD 10
11 Pre-treatment Reduced voiding pressure after botulinum A toxin injection C5#, ASIA Class A, DH + DESD Poor bladder emptying, RU 426 ml Reduced MUCP after Botulinum A toxin injection Therapeutic Results after Botox Urethral Injection for Voiding Dysfunction Good Improved Failed Detrusor underactivity (n=27) DESD (n=18) Dysfunctional voiding (n=18) 13 (48.2%) 8 (29.6%) 6 (22.2%) (16.7%) (55.6%) (27.8%) 6 (33.3%) 10 (55.6%) 2 (11%) Poor relaxation of urethral sphincter (n=12) 3 (25%) 7 (58.3%) 2 (16.6%) TOTAL (n=75) 25 (33.3%) 35 (43.7%) 15 (20%) DESD=Detrusor external sphincter dyssynergia Kuo et al months post injection of Dysport to external urethral sphincter 9 months post-injection of Botox: resting UPP study CMG : 9 months post-injection of Botox/ Dysport ( Dysport: 500 IU in 8 ml NS -> 62.5 ml in 1 ml NS ; 3ml injected ) 11
12 9 months following injection of Dysport to external urethral sphincter Botox Detrusor External Sphincter Dys-synergia CMG 2: 9 months post-injection of Dysport ( voiding phase ) ( Dysport: 500 IU in 8 ml NS -> 62.5 ml in 1 ml NS ; 3ml injected ) Leippold et al Eur Urol 2003; 44: Detrusor External Sphincter Dys-synergia Authors No. pts Dose ( U ) Outcome Duration ( months ) Dykstra et al autonomic dysreflexia; 2 PVR; UPP Dykstra et al autonomic dysreflexia; 3 PVR; UPP Pre-injection 3 months following treatment ( injection to external urethral sphincter ) Schurch et al / 250 UPP; NO autonomic dysreflexia Gallien et al autonomic dysreflexia; 40% able to do CISC Rackley et al Improved UDI Score; improved bladder perception scores; PVR 2-3 / ( 3-5) 3 6 Smith et al need dto do CISC; 6 pdetmax; PVR Kuo et al voiding pressure; PVR; UPP; improved QoL Kuo et al % discontinued CISC; voiding pressure; PVR; UPP Phelan et al PVR; voiding pressure; 85% discontinued CISC Petit et al CISC frequency; PVR unchanged; voiding pressure; 3 4 ( 2 6 ) NA 2-5 CMG: 3 months post-injection of Dysport ( Dysport: 500 IU in 8 ml NS -> 62.5 ml in 1 ml NS ; 3ml injected ) UDI : Urinary Distress Inventory Botulinum toxin vs DESD Botulinum toxin vs DESD 12
13 Botox Side Effects Flu-like Symptoms Urinary Tract Infection Generalized Muscle Weakness ( 8 pts ) De Laet K et al Spinal Cord 43: Neurostimulation Brindley Sacral posterior root rhizotomy ( sacral deafferentation ) Sacral anterior root stimulation ( SARS ) Supra-sacral lesion with intact efferent neurons and a bladder that is able to contract Abolish reflex voiding Neuromodulation Bemelmans et al 1999 it is not really known how it works, however, there is strong evidence that neuromodulation works at a spinal and at a supraspinal level Leakage due to detrusor hyperreflexia 83% improved ( but still leakage ++ ) Voiding failure 80% improved ( but still need intermittent catheterization) Pain? intradurally $ Extradurally Urodynamics- Videourodynamics CYK M/24 # T6, complete paraplegia, recurrent UTI incontinence Team Work 13
14 Thank You 14
Botulinum Toxin: Applications in Urology
Botulinum Toxin: Applications in Urology Dr. Lee Jonat, PGY-4 Department of Urologic Sciences University of British Columbia Outline Mechanism of Action Technical Considerations Adverse Events Neurogenic
More informationGuidelines on Neurogenic Lower Urinary Tract Dysfunction
Guidelines on Neurogenic Lower Urinary Tract Dysfunction (Text update March 2009) M. Stöhrer (chairman), B. Blok, D. Castro-Diaz, E. Chartier- Kastler, P. Denys, G. Kramer, J. Pannek, G. del Popolo, P.
More information2/9/2008. Men Women. Prevalence of OAB. Men: 16.0% Women: 16.9% Prevalence (%) < Age (years)
Definition Botox for Overactive Bladder Donna Y. Deng Assistant Professor UCSF Department of Urology Urinary urgency With or without urge incontinence Usually with frequency & nocturia International Continence
More informationSpinal Cord Injury. R Hamid Consultant Neuro-Urologist London Spinal Injuries Unit, Stanmore & National Hospital for Neurology & Neurosurgery, UCLH
Spinal Cord Injury R Hamid Consultant Neuro-Urologist London Spinal Injuries Unit, Stanmore & National Hospital for Neurology & Neurosurgery, UCLH SCI 800 1000 new cases per year in UK Car accidents 35%
More informationThe Neurogenic Bladder
The Neurogenic Bladder Outline Brandon Haynes, MD Resident Physician Department of Urology Jelena Svircev, MD Assistant Professor Department of Rehabilitation Medicine Anatomy and Bladder Physiology Bladder
More informationSummary. Neuro-urodynamics. The bladder cycle. and voiding. 14/12/2015. Neural control of the LUT Initial assessment Urodynamics
Neuro-urodynamics Summary Neural control of the LUT Initial assessment Urodynamics Marcus Drake, Bristol Urological Institute SAFETY FIRST; renal failure, dysreflexia, latex allergy SYMPTOMS SECOND; storage,
More informationUrinary Aspects of Multiple Sclerosis chronic condition with innovative treatment strategies. Dr. Boris Friedman May 2, 2012 OBJECTIVES
Urinary Aspects of Multiple Sclerosis chronic condition with innovative treatment strategies Dr. Boris Friedman May 2, 2012 OBJECTIVES 1) Definition and classification of MS 2) Interventional radiology
More informationGuidelines on Urinary Incontinence
Guidelines on Urinary Incontinence J. Thüroff (chairman), P. Abrams, K.E. Andersson, W. Artibani, E. Chartier-Kastler, C. Hampel, Ph. van Kerrebroeck European Association of Urology 2006 TABLE OF CONTENTS
More informationNeuropathic Bladder. Magda Kujawa Consultant Urologist Stockport NHS Foundation Trust 12/03/2014
Neuropathic Bladder Magda Kujawa Consultant Urologist Stockport NHS Foundation Trust 12/03/2014 Plan Physiology- bladder and sphincter behaviour in neurological disease Clinical consequences of Symptoms
More informationGUIDELINES ON NEUROGENIC LOWER URINARY TRACT DYSFUNCTION
GUIDELINES ON NEUROGENIC LOWER URINARY TRACT DYSFUNCTION M. Stöhrer (chairman), D. Castro-Diaz, E. Chartier-Kastler, G. Kramer, A. Mattiasson, J-J. Wyndaele Introduction NLUTD (neurogenic lower urinary
More informationNEUROGENIC BLADDER. Dr Harriet Grubb Dr Alison Seymour Dr Alexander Joseph
NEUROGENIC BLADDER Dr Harriet Grubb Dr Alison Seymour Dr Alexander Joseph OUTLINE Definition Anatomy and physiology of bladder function Types of neurogenic bladder Assessment and management Complications
More informationCASES FOR TRAINING OF THE INTERNATIONAL SPINAL CORD INJURY LOWER URINARY TRACT FUNCTION BASIC DATA SET CASE 1
1 CASES FOR TRAINING OF THE INTERNATIONAL SPINAL CORD INJURY LOWER URINARY TRACT FUNCTION BASIC DATA SET CASE 1 35 years old man, who previously has been completely healthy, was shot twice in the neck
More informationRecommandations de prise en charge des vessies neurogènes EAU 2006
Annexe 4-1 Recommandations de prise en charge des vessies neurogènes EAU 2006 (Version courte) 685 686 GUIDELINES ON NEUROGENIC LOWER URINARY TRACT DYSFUNCTION M. Stöhrer (chairman), D. Castro-Diaz, E.
More informationStimulation of the Sacral Anterior Root Combined with Posterior Sacral Rhizotomy in Patients with Spinal Cord Injury. Original Policy Date
MP 7.01.58 Stimulation of the Sacral Anterior Root Combined with Posterior Sacral Rhizotomy in Patients with Spinal Cord Injury Medical Policy Section Issue 12:2013 Original Policy Date 12:2013 Last Review
More informationGUIDELINES ON NEURO-UROLOGY
GUIDELINES ON NEURO-UROLOGY (Text update pril 2014) J. Pannek (co-chair), B. Blok (co-chair), D. Castro-Diaz, G. del Popolo, J. Groen, G. Karsenty, T.M. Kessler, G. Kramer, M. Stöhrer Eur Urol 2009 Jul;56(1):81-8
More informationNeural control of the lower urinary tract in health and disease
Neural control of the lower urinary tract in health and disease Jalesh N. Panicker MD, DM, FRCP Consultant Neurologist and Clinical lead in Uro-Neurology The National Hospital for Neurology and Neurosurgery
More informationAdult Urodynamics: American Urological Association (AUA)/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Guideline
Adult Urodynamics: American Urological Association (AUA)/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Guideline TARGET POPULATION Eligibility Decidable (Y or N) Inclusion
More informationUrodynamics in Neurological Lower Urinary Tract Dysfunction. Mr Chris Harding Consultant Urologist Freeman Hospital Newcastle-upon-Tyne
Urodynamics in Neurological Lower Urinary Tract Dysfunction Mr Chris Harding Consultant Urologist Freeman Hospital Newcastle-upon-Tyne Learning Objectives Review functional neurology relevant to lower
More informationManagement, Evaluation, and Treatment of Overactive Bladder and Urinary Incontinence
Management, Evaluation, and Treatment of Overactive Bladder and Urinary Incontinence Arthur Mourtzinos, MD, MBA Co-Vice Chair, Institute of Urology Director, Continence Center Assistant Professor of Urology,
More informationHospital and Tzu Chi University, Hualien, Taiwan
LUTS (2012) 4, 29 34 ORIGINAL ARTICLE Difficult Urination Does Not Affect the Successful Outcome after 100U OnabotulinumtoxinA Intravesical Injection in Patients with Idiopathic Detrusor Overactivity Yih-Chou
More informationThe Successful and Novel Treatment of Non-Neurogenic Detrusor- External Sphincter Dyssynergia (DESD) with Botulinum Toxin A
original article The Successful and Novel Treatment of Non-Neurogenic - External Sphincter Dyssynergia (DESD) with Botulinum Toxin A Tricia LC Kuo, MBBS, MRCSEd, M Med (Surg), FAMS, Lay Guat Ng, MBBS,
More informationNeural control of the lower urinary tract
Neural control of the lower urinary tract Jalesh N. Panicker Consultant Neurologist and Honorary Senior Lecturer The National Hospital for Neurology and Neurosurgery and UCL Institute of Neurology Queen
More informationOveractive Bladder (OAB) and Quality of Life
Overactive Bladder (OAB) and Quality of Life Dr. Byron Wong MBBS (Sydney), FRCSEd, FRCSEd (Urol), FCSHK, FHKAM (Surgery) Specialist in Urology Central Urology Clinic Hong Kong Continence Society Annual
More informationGUIDELINES ON NEURO-UROLOGY
GUIDELINES ON NEURO-UROLOGY (Limited text update March 2015) B. Blok (Co-chair), J. Pannek (Co-chair), D. Castro Diaz, G. del Popolo, J. Groen, T. Gross (Guidelines ssociate), R. Hamid, G. Karsenty, T.M.
More informationBotulinum Toxin Treatment for Overactive Bladder: Efficacy, Mechanism of Action, Techniques and Practical Tips W16, 15 October :00-17:00
Botulinum Toxin Treatment for Overactive Bladder: Efficacy, Mechanism of Action, Techniques and Practical Tips W16, 15 October 2012 14:00-17:00 Start End Topic Speakers 14:00 14:15 Introduction Mohammad
More informationPelvic Floor Therapy for the Neurologic Client Carina Siracusa, PT, DPT, WCS
Pelvic Floor Therapy for the Neurologic Client Carina Siracusa, PT, DPT, WCS OhioHealth, Columbus Ohio Disclosures I have nothing to disclose Objectives Describe the role of a pelvic floor therapist in
More informationEAU GUIDELINES ON NEURO-UROLOGY
EAU GUIDELINES ON NEURO-UROLOGY (Limited text update March 2016) B. Blok (Co-chair), J. Pannek (Co-chair) D. Castro-Diaz, G. del Popolo, J. Groen, R. Hamid, G. Karsenty, T.M. Kessler. Guidelines Associates:
More informationBOTOX (onabotulinumtoxina) for Therapeutic Use
BOTOX (onabotulinumtoxina) for Therapeutic Use BOTOX (onabotulinumtoxina) & BOTOX Cosmetic (onabotulinumtoxina) Important Information IMPORTANT SAFETY INFORMATION BOTOX and BOTOX Cosmetic may cause serious
More informationNeurogenic bladder. Neurogenic bladder is a type of dysfunction of the bladder due to neurological disorder.
Definition: Neurogenic bladder Neurogenic bladder is a type of dysfunction of the bladder due to neurological disorder. Types: Nervous system diseases: Congenital: like myelodysplasia like meningocele.
More informationNEUROMODULATION FOR UROGYNAECOLOGISTS
NEUROMODULATION FOR UROGYNAECOLOGISTS Introduction The pelvic floor is highly complex structure made up of skeletal and striated muscle, support and suspensory ligaments, fascial coverings and an intricate
More informationClinical Study Predictors of Response to Intradetrusor Botulinum Toxin-A Injections in Patients with Idiopathic Overactive Bladder
Advances in Urology Volume 2009, Article ID 328364, 4 pages doi:10.1155/2009/328364 Clinical Study Predictors of Response to Intradetrusor Botulinum Toxin-A Injections in Patients with Idiopathic Overactive
More informationPhysiology & Neurophysiology of lower U.T.
Physiology & Neurophysiology of lower U.T. Classification of voiding dysfunction Evaluation of a child with voiding dysfunction Management Storage Ø Adequate volume of urine Ø At LOW pressure Ø With NO
More informationTHE ACONTRACTILE BLADDER - FACT OR FICTION?
THE ACONTRACTILE BLADDER - FACT OR FICTION? Jacob Golomb Department of Urology Chaim Sheba Medical Center Tel Hashomer NEUROGENIC UNDERACTIVE DETRUSOR Central (complete/incomplete): Spinal cord injury-
More informationBOTULINUM TOXIN IN LOWER URINARY TRACT
BOTULINUM TOXIN IN LOWER URINARY TRACT Selcuk Yucel, MD Professor in Urology and Pediatric Urology Acibadem University School of Medicine Department of Uroloy and Pediatric Urology Acibadem University
More informationOveractive Bladder Syndrome
Overactive Bladder Syndrome behavioural modifications to pharmacological and surgical treatments Dr Jos Jayarajan Urologist Austin Health, Eastern Health Warringal Private, Northpark Private, Epworth Overactive
More informationEAU GUIDELINES ON NEURO-UROLOGY
EAU GUIDELINES ON NEURO-UROLOGY (Limited text update March 2017) B. Blok (Co-chair), J. Pannek (Co-chair) D. Castro-Diaz, G. del Popolo, J. Groen, R. Hamid, G. Karsenty, T.M. Kessler Guidelines Associates:
More informationTuesday 24 June Poster Session 1: Voiding Dysfunction Chairmen: C. Chapple and L. Stewart
Tuesday 24 June 10.30 11.30 Poster Session 1: Voiding Dysfunction Chairmen: C. Chapple and L. Stewart P001 Can oral antibiotic prophylaxis reduce the rate of infection after conventional urodynamic studies?
More informationTREATMENT METHODS FOR DISORDERS OF SMALL ANIMAL BLADDER FUNCTION
Vet Times The website for the veterinary profession https://www.vettimes.co.uk TREATMENT METHODS FOR DISORDERS OF SMALL ANIMAL BLADDER FUNCTION Author : SIMONA T RADAELLI Categories : Vets Date : July
More informationBotox. Botox (onabotulinum toxin A) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.01 Subject: Botox Page: 1 of 8 Last Review Date: September 15, 2017 Botox Description Botox (onabotulinum
More informationDiagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline.
Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. TARGET POPULATION Eligibility Decidable (Y or N) Inclusion Criterion non-neurogenic OAB Exclusion Criterion
More informationUrodynamic and electrophysiological investigations in neuro-urology
Urodynamic and electrophysiological investigations in neuro-urology Pr. Gerard Amarenco Neuro-Urology and Pelvic-Floor Investigations Department Tenon Hospital, Assistance Publique Hôpitaux de Paris, Er6,
More informationA Simplified Technique for Botulinum Toxin Injections in Children With Neurogenic Bladder
A Simplified Technique for Botulinum Toxin Injections in Children With Neurogenic Bladder Maria Paola Pascali, Giovanni Mosiello,* Armando Marciano, Maria Luisa Capitanucci, Antonio Maria Zaccara and Mario
More informationThe Effect ofverapamil on the Treatment of Detrusor Hyperreflexia in the Spinal Cord Injured Population
Paraplegia 27 (1989) 364-369 0031-1758/89/0027-0364$10.00 ([j 1989 International Medical Society of Paraplegia The Effect ofverapamil on the Treatment of Detrusor Hyperreflexia in the Spinal Cord Injured
More informationObjectives. Prevalence of Urinary Incontinence URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS
URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS Lisa S Pair, MSN, CRNP Division of Urogynecology and Pelvic Reconstructive Surgery Department of Obstetrics and Gynecology University of Alabama
More informationIntroduction. Spinal Cord Injury (SCI) Is it necessary to perform surveillance investigations for long term follow up of spinal cord injury patients?
Is it necessary to perform surveillance investigations for long term follow up of spinal cord injury patients? Rizwan Hamid MBBS, FRCSEd, FRCS(Urol), MD(Res) Honorary Senior Lecturer & Consultant Urologist
More informationClare Gaduzo BSc RMN Registered Aesthetics Practitioner (qualified with Medics Direct)
Clare Gaduzo BSc RMN Registered Aesthetics Practitioner (qualified with Medics Direct) 07935567067 cjg.aesthetics@yahoo.co.uk www.cjgaesthetics.co.uk http://www.facebook.com/cjgaesthetics @CJGAesthetics
More informationScientific Update Laxman Bahroo, MD
Scientific Update Laxman Bahroo, MD Associate Professor Director; Botulinum Toxin Clinic Director; Neurology Residency Program Medstar Georgetown University Hospital Washington, D.C. Disclosures Advisory
More informationUK Consensus on Bladder Management in MS
Continence Care Forum Annual Conference UK Consensus on Bladder Management in MS Clare J.Fowler National Hospital for Neurology and Neurosurgery & Institute of Neurology, UCL Association of British Neurologists
More informationAppendix 1. Patient Instruction for Botulinum Toxin Bladder Injection. The Day of Treatment Session
Appendix 1 Patient Instruction for Botulinum Toxin Bladder Injection NOTE: If you usually take oral antibiotics prior to dental appointments, we would like you to do the same before the bladder injection
More informationWhat should we consider before surgery? BPH with bladder dysfunction. Inje University Sanggye Paik Hospital Sung Luck Hee
What should we consider before surgery? BPH with bladder dysfunction Inje University Sanggye Paik Hospital Sung Luck Hee Diagnostic tests in three categories Recommendation: there is evidence to support
More informationBladder dysfunction in ALD and AMN
Bladder dysfunction in ALD and AMN Sara Simeoni, MD Department of Uro-Neurology National Hospital for Neurology and Neurosurgery Queen Square, London 10:15 Dr Sara Simeoni- Bladder issues for AMN patients
More informationURGE MOTOR INCONTINENCE
URGE MOTOR INCONTINENCE URGE INCONTINENCE COMMONEST TYPE IN ELDERLY WOMEN Causes: 1 - Defects in CNS regulation Stroke Parkinson s disease Dementia (Alzheimer s and other types) Normopressure hydrocephalus
More informationElectrostimulation Part 3: Bladder dysfunctions
GBM8320 Dispositifs Médicaux Intelligents Electrostimulation Part 3: Bladder dysfunctions Mohamad Sawan et al Laboratoire de neurotechnologies Polystim!!! http://www.cours.polymtl.ca/gbm8320/! mohamad.sawan@polymtl.ca!
More informationOriginal Article. Annals of Rehabilitation Medicine INTRODUCTION
Original Article Ann Rehabil Med 2014;38(3):342-346 pissn: 2234-0645 eissn: 2234-0653 http://dx.doi.org/10.5535/arm.2014.38.3.342 Annals of Rehabilitation Medicine Phasic Changes in Bladder Compliance
More informationBotulinum Toxin Injection for OAB: Indications & Technique
Classification of LUTS Botulinum Toxin Injection for OAB: Indications & Technique Sherif Mourad, MD Professor of Urology, Ain Shams University General Secretary of International Continence President of
More informationGBM8320 Dispositifs Médicaux Intelligents. Electrostimulation. Part 3: Bladder dysfunctions
GBM8320 Dispositifs Médicaux Intelligents Electrostimulation Part 3: Bladder dysfunctions Mohamad Sawan et al Laboratoire de neurotechnologies Polystim!!! http://www.cours.polymtl.ca/gbm8320/! mohamad.sawan@polymtl.ca!
More informationURINARY INCONTINENCE
Center for Continence Care and Pelvic Medicine What is urinary incontinence? URINARY INCONTINENCE Urinary incontinence is the uncontrollable loss of urine. The amount of urine leaked can vary from only
More informationINTRAVESICAL INJECTION OF BOTULINUM TOXIN TYPE A: MANAGEMENT OF NEUROPATHIC BLADDER AND BOWEL DYSFUNCTION IN CHILDREN WITH MYELOMENINGOCELE
PEDIATRIC UROLOGY INTRAVESICAL INJECTION OF BOTULINUM TOXIN TYPE A: MANAGEMENT OF NEUROPATHIC BLADDER AND BOWEL DYSFUNCTION IN CHILDREN WITH MYELOMENINGOCELE ABDOL-MOHAMMAD KAJBAFZADEH, SHAHRAM MOOSAVI,
More informationCase Based Urology Learning Program
Case Based Urology Learning Program Resident s Corner: UROLOGY Case Number 23 CBULP 2011 077 Case Based Urology Learning Program Editor: Associate Editors: Manager: Case Contributors: Steven C. Campbell,
More informationIncontinence. When I was given this topic in urology to discuss with you today I
Incontinence When I was given this topic in urology to discuss with you today I was slightly disappointed. I personally see mostly men for problems such as stones, benign prostatic hyperplasia, prostate
More informationWhat is on the Horizon in Drug Therapy for OAB?
What is on the Horizon in Drug Therapy for OAB? K-E Andersson, MD, PhD Wake Forest Institute for Regenerative Medicine Wake Forest University School of Medicine Winston Salem, North Carolina Disclosures
More informationVarious Types. Ralph Boling, DO, FACOG
Various Types Ralph Boling, DO, FACOG The goal of this lecture is to increase assessment and treatment abilities for physicians managing urinary incontinence (UI) patients. 1. Effectively communicate with
More informationeuropean urology 52 (2007)
european urology 52 (2007) 1729 1735 available at www.sciencedirect.com journal homepage: www.europeanurology.com Neuro-urology Do Repeat Intradetrusor Botulinum Toxin Type A Injections Yield Valuable
More informationTechnologies and architectures" Stimulator, electrodes, system flexibility, reliability, security, etc."
March 2011 Introduction" Basic principle (Depolarization, hyper polarization, etc.." Stimulation types (Magnetic and electrical)" Main stimulation parameters (Current, voltage, etc )" Characteristics (Muscular
More informationManagement of OAB. Lynsey McHugh. Consultant Urological Surgeon. Lancashire Teaching Hospitals
Management of OAB Lynsey McHugh Consultant Urological Surgeon Lancashire Teaching Hospitals Summary Physiology Epidemiology Definitions NICE guidelines Evaluation Conservative management Medical management
More informationIncontinence in neurological disease
nice bulletin Incontinence in neurological disease NICE provided the content for this booklet which is independent of any company or product advertised NICE Bulletin - Incontinence in neurological disease.indd
More informationPractical urodynamics What PA s need to know. Gary E. Lemack, MD Professor of Urology and Neurology
Practical urodynamics What PA s need to know Gary E. Lemack, MD Professor of Urology and Neurology Urodynamics essential elements Urethral catheter Fill rate Catheter size Intravesical pressure measurements
More informationNEUROPATHIC BLADDER DISORDERS
NEUROPATHIC BLADDER DISORDERS ANATOMY & PHYSIOLOGY The Bladder Unit The functional features of the bladder include (1) a normal capacity of 400 500 ml, (2) a sensation of fullness, (3) the ability to accommodate
More informationBladder Management. A guide for patients. Key points
Bladder Management A guide for patients Key points Urinary issues remain one of the highest causes of readmission to hospital following Spinal Cord Injury (SCI). Following SCI most patients experience
More informationAdverse Events of Intravesical Botulinum Toxin A Injections for Idiopathic Detrusor Overactivity: Risk Factors and Influence on Treatment Outcome
EUROPEAN UROLOGY 58 (2010) 919 926 available at www.sciencedirect.com journal homepage: www.europeanurology.com Incontinence Adverse Events of Intravesical Botulinum Toxin A Injections for Idiopathic Detrusor
More informationeuropean urology 50 (2006)
european urology 50 (2006) 806 810 available at www.sciencedirect.com journal homepage: www.europeanurology.com Neuro-urology Successful Treatment with Intradetrusor Botulinum-A Toxin for Urethral Urinary
More informationBotulinum toxin-a for the treatment of overactive bladder: UK contributions
473096URO6210.1177/2051415812473096Journal of Clinical UrologySeth et al. 2013 Original Article Botulinum toxin-a for the treatment of overactive bladder: UK contributions Journal of Clinical Urology 6(2)
More informationClinical guideline Published: 8 August 2012 nice.org.uk/guidance/cg148
Urinary incontinence in neurological disease: assessment and management Clinical guideline Published: 8 August 2012 nice.org.uk/guidance/cg148 NICE 2018. All rights reserved. Subject to Notice of rights
More informationMEDICATION GUIDE BOTOX BOTOX Cosmetic (Boe-tox) (onabotulinumtoxina) for Injection
17.2 Ability to Operate Machinery or Vehicles Advise patients that if loss of strength, muscle weakness, blurred vision, or drooping eyelids occur, they should avoid driving a car or engaging in other
More informationTools for Evaluation. Urodynamics Case Studies. Case 1. Evaluation. Case 1. Bladder Diary SUI 19/01/2018
Urodynamics Case Studies Christopher K. Payne, MD Vista Urology & Pelvic Pain Partners Emeritus Professor of Urology, Stanford University Tools for Evaluation Ears, Eyes, and Brain Bladder diary Stress
More informationeuropean urology 53 (2008)
european urology 53 (2008) 275 287 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Neuro-urology Botulinum Toxin A (Botox W ) Intradetrusor Injections in Adults with
More informationNeurological control of the bladder in health and disease
Section 1 Chapter 1 Neurological control of pelvic organ functions Neurological control of the bladder in health and disease Derek J. Griffiths and Apostolos Apostolidis Peripheral control of micturition
More informationTHE vesical dysfunction which follows injury or disease of the spinal cord
VESICAL NECK RESECTION FOR NEUROGENIC BLADDER WILLIAM J. ENGEL, M.D. Department of Urology THE vesical dysfunction which follows injury or disease of the spinal cord or cauda equina has always presented
More informationNON-Neurogenic Chronic Urinary Retention AUA White Paper
NON-Neurogenic Chronic Urinary Retention AUA White Paper Great Lakes SUNA Inside Urology March 16, 2018 Michelle J. Lajiness FNP-BC Nurse Practitioner DMC Urology Incidence Really unknown Lack consensus
More informationNeurogenic Bladder: What You Should Know. A Guide for People with Spinal Cord Injury
Neurogenic Bladder: What You Should Know A Guide for People with Spinal Cord Injury Why Is This Information Important? Before SCI, you didn t have to think about managing your bladder After SCI, you may
More informationProspective randomized trial of 100u vs 200u botox in the treatment of idiopathic overactive bladder
Original Article Prospective randomized trial of vs botox in the treatment of idiopathic overactive bladder Waleed AlTaweel, Alaa Mokhtar, Danny M. Rabah 1 King Faisal Specialist Hospital and Research
More informationMedical History of Botulinum Toxin
REVIEW ARTICLE BOTULINUM TOXIN TREATMENT OF URETHRAL AND BLADDER DYSFUNCTION Yao-Chi Chuang, 1 Christopher P. Smith, 2 George T. Somogyi, 3 and Michael B. Chancellor 2 Abstract: Botulinum toxin (BTX) is
More informationThis Special Report supplement
...INTRODUCTION... Overactive Bladder: Defining the Disease Alan J. Wein, MD This Special Report supplement to The American Journal of Managed Care features proceedings from the workshop, Overactive Bladder:
More informationREVIEW. Botulinum toxin: historical perspective and treatment of neurogenic and idiopathic overactive bladder
REVIEW Botulinum toxin: historical perspective and treatment of neurogenic and idiopathic overactive bladder Overactive bladder (OAB) afflicts nearly 17% of the population, causing frequent urgent dashes
More informationinformation Sacral Anterior Root Stimulator (SARS) and Dorsal Rhizotomy (1 of 5) What is a sacral anterior root stimulator? How does the implant work?
information Sacral Anterior Root Stimulator (SARS) and Dorsal Rhizotomy (1 of 5) What is a sacral anterior root stimulator? If you need this information in another language or medium (audio, large print,
More informationWhat neurologists need to understa
98 PRACTICAL NEUROLOGY INTRODUCTION Urodynamics has been used in the investigation of bladder dysfunction since the 1950s, although the first report describing bladder pressure measurement dates from 1882
More informationHow to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxina
Reviews How to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxina Mikolaj Przydacz A F, Tomasz Golabek A,E,F, Piotr Chlosta A,E,F Department of Urology, Jagiellonian
More informationBotulinum Toxin Injection: A Review of Injection Principles and Protocols
Review Article Botulinum Toxin Injection International Braz J Urol Vol. 33 (2): 132-141, March - April, 2007 Botulinum Toxin Injection: A Review of Injection Principles and Protocols David E. Rapp, Alvaro
More informationBOTOX. Description. Section: Prescription Drugs Effective Date: January 1, 2013 Subsection: CNS Original Policy Date: December 7, 2011
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.12.01 Subject: Botox Page: 1 of 6 Last Review Status/Date: December 6, 2012 BOTOX Description Botox (onabotulinum
More informationIncontinence; Lets talk about it. Karanvir Virk M.D. Minimally Invasive and Pelvic Reconstructive Surgery
Incontinence; Lets talk about it Karanvir Virk M.D. Minimally Invasive and Pelvic Reconstructive Surgery Select the most appropriate subtitle for this talk A: Bladders gone wild! B: There s no such thing
More informationUse of botulinum toxin for voiding dysfunction
Review Article Use of botulinum toxin for voiding dysfunction David Eldred-Evans, Prokar Dasgupta Department of Urology, Medical Research Council (MRC) Centre for Transplantation, King s College London,
More informationDisclosures. Background. Expanding the Xiao Concept to Spina Bifida
Lumbar to Sacral Nerve Rerouting to Restore Voiding and Bowel Function in Spina Bifida Kenneth M. Peters, MD Professor and Chairman of Urology Oakland University William Beaumont School of Medicine Royal
More informationUrinary Incontinence. Vibhash Mishra Consultant Urological Surgeon Royal Free Hospital
Urinary Incontinence Vibhash Mishra Consultant Urological Surgeon Royal Free Hospital Affects women of all ages Impacts physical, psychological & social wellbeing Impact on families & carers Costs the
More informationWe have heard a great deal about "overactive" bladder recently. But what
BLADDER DYSFUNCTION Differential Diagnosis and Treatment of Impaired Bladder Emptying Naoki Yoshimura, MD, PhD, Michael B. Chancellor, MD Department of Urology, University of Pittsburgh School of Medicine,
More informationEFFECTS OF BOTULINUM TOXIN A INJECTIONS IN SPINAL CORD INJURY PATIENTS WITH DETRUSOR OVERACTIVITY AND DETRUSOR SPHINCTER DYSSYNERGIA
J Rehabil Med 2016; 48: 683 687 ORIGINAL REPORT EFFECTS OF BOTULINUM TOXIN A INJECTIONS IN SPINAL CORD INJURY PATIENTS WITH DETRUSOR OVERACTIVITY AND DETRUSOR SPHINCTER DYSSYNERGIA Maping Huang, PhD 1,
More informationLower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist
Lower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist Lower Urinary Tract Symptoms Storage Symptoms Frequency, urgency, incontinence, Nocturia Voiding Symptoms Hesitancy, poor flow, intermittency,
More informationPaediatric Urotherapy Training
Paediatric Urotherapy Training Frances Shit NS, MSc (Hons), ET, Dept. of Surgery, PWH, CUHK HKSAR Urinary Incontinence in Children Urine leakage in a child from 5 years of age Leakage occurs on a regular
More informationElimination Patterns: Bladder
Elimination Patterns: Bladder CRRN Review Material Christa Carter, RN, BSN, CRRN Objectives Identify different types of neurogenic bladder Identify different types of incontinence Identify at least three
More informationSELECTED POSTER PRESENTATIONS
SELECTED POSTER PRESENTATIONS The following summaries are based on posters presented at the American Urogynecological Society 2004 Scientific Meeting, held July 29-31, 2004, in San Diego, California. CENTRAL
More information